Protocol Ledger

NCT06078384 · Phase II · RECRUITING

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Interventional Phase II clinical trial protocol NCT06078384 sponsored by UNICANCER in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-27 Enrollment: 354 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06078384
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)354 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06078384
Protocol FieldVerified Registry Value
NCT IdentifierNCT06078384
Consolidated Lead SponsorUNICANCER
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment354 participants (ESTIMATED)
Registered Start Date2024-12-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06078384
Hospital Research SiteLocationSite Profile
Institut Sainte CatherineAvignon, FranceOpen Hospital Dossier ->
Institut BergoniéBordeaux, FranceOpen Hospital Dossier ->
Centre François BaclesseCaen, FranceOpen Hospital Dossier ->
Centre Jean PerrinClermont-Ferrand, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI